Cerus Corporation  (CERS)
Other Ticker:  
Price: $1.9300 $-0.03 -1.531%
Day's High: $1.985 Week Perf: -2.53 %
Day's Low: $ 1.86 30 Day Perf: -15.72 %
Volume (M): 1,149 52 Wk High: $ 5.95
Volume (M$): $ 2,217 52 Wk Avg: $3.73
Open: $1.93 52 Wk Low: $1.76

 Market Capitalization (Millions $) 344
 Shares Outstanding (Millions) 178
 Employees 309
 Revenues (TTM) (Millions $) 261
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 3

Cerus Corporation
Cerus Corporation is a biopharmaceutical company that has been dedicated to providing solutions for the enhancement of blood safety throughout the world since 1991. Their headquarters are located in Concord, California, and the company has additional facilities in France, Germany, and Switzerland.

Cerus Corporation focuses on the development of innovative technologies that can help prevent the transmission of diseases through blood transfusions. Their primary product is the INTERCEPT Blood System, which provides a broad-spectrum solution for the reduction of pathogens present in donated blood. It is a unique and proprietary technology that works by incorporating an FDA-approved chemical compound, known as amotosalen, to inactivate viruses, bacteria, and parasites in blood products.

The INTERCEPT Blood System targets the transfusion needs of individual patients by customizing blood components to meet their specific needs. This technology can also reduce the risk of transfusion-transmitted infections, such as dengue, Zika, chikungunya, and malaria. As such, it is becoming increasingly adopted in countries around the world, especially those with a high risk of disease transmission through transfusions.

Cerus Corporation's products and technologies have been approved by several regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company collaborates with several Worldwide Health Organisations, blood centers, and hospitals around the world. The INTERCEPT Blood System is used by over 150 centers in 30 countries, with over 5 million INTERCEPT-treated platelet and plasma units in circulation.

The company's management team comprises experts with vast experience in the health sector, which includes the commercialization of innovative blood products, and the successful registration of new pharmaceutical and medical device products globally.

Cerus Corporation is committed to continuously providing innovative products and services to meet necessary patient needs. With a commitment to excellence in research, development, and regulatory clinical trial programs, Cerus Corporation is at the forefront of reducing the risk of blood-borne diseases and ensuring patient safety in transfusion therapies.

   Company Address: 1220 Concord Avenue Concord 94520 CA
   Company Phone Number: 288-6000   Stock Exchange / Ticker: NASDAQ CERS
   CERS is expected to report next financial results on August 03, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.

Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.

T2 Biosystems Inc

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

While the stock market can be a turbulent place, there is one company that has had a rough start to 2023. T2 Biosystems Inc recently reported a substantial decrease in revenue, a net loss per share expansion, and a significant drop in sequential revenue, causing some investors to worry.
But let's take a closer look at what these numbers actually mean. While the Mar 31 2023 report was certainly a disappointment, it's important to remember that these are just one quarter's worth of financials. There are always ups and downs in the stock market, and companies often experience setbacks before bouncing back stronger than ever.

H Cyte Inc

The revenue are the similar like a year prior at the Medical Equipment and Supplies company over the January to March 31 2023 span

H Cyte Inc is a company involved in the developing and commercialization of medical therapeutics, specifically in the field of regenerative medicine. The company's focus is on developing therapies for joint and spine-related conditions. The company is headquartered in California and began trading on the NASDAQ Global Market in February 2022 under the ticker symbol HCYT.
In the first quarter of 2023, H Cyte Inc reported that its net deficit had expanded to $-3.38 per share, compared to $0.00 per share in the same period of the previous year. However, the company's EPS improved to $-5.08 per share from the previous reporting season. In terms of revenue, the company's earnings remained unchanged at $0.00 million from the previous year's reporting season and sequentially. The company also reported a net deficit of $-2.090 million in the first quarter of 2023, compared to a deficit of $-3.892 million in the same period of the previous year.

Therapeutic Solutions International Inc

Severe hit for Therapeutic Solutions International Inc all along the financial span ending March 31 2023

Therapeutic Solutions International Inc, a pharmaceutical company, recently published its fiscal interval report ending on March 31, 2023. The report indicated that the company was able to maintain balanced books, showing no earnings or losses per share. This is the same as the previous fiscal year, but an improvement from the previous reporting period.
The company's revenue, on the other hand, decreased by 72.764% from $0.08 million in the comparative period to $0.02 million. However, sequentially, there was a significant increase of 169.53% from $0.01 million. This indicates that the company's financial performance has been unstable overall.


Cerus's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071